- Home
- PINE vs LYEL Comparison
PINE vs LYEL Comparison
Compare PINE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- LYEL
- Stock Information
- Founded
- PINE 2019
- LYEL 2018
- Country
- PINE United States
- LYEL United States
- Employees
- PINE N/A
- LYEL N/A
- Industry
- PINE Real Estate Investment Trusts
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- LYEL Health Care
- Exchange
- PINE Nasdaq
- LYEL Nasdaq
- Market Cap
- PINE 245.5M
- LYEL 207.7M
- IPO Year
- PINE 2019
- LYEL 2021
- Fundamental
- Price
- PINE $16.70
- LYEL $0.53
- Analyst Decision
- PINE Strong Buy
- LYEL Sell
- Analyst Count
- PINE 9
- LYEL 2
- Target Price
- PINE $19.72
- LYEL $1.00
- AVG Volume (30 Days)
- PINE 72.8K
- LYEL 879.2K
- Earning Date
- PINE 04-17-2025
- LYEL 03-11-2025
- Dividend Yield
- PINE 6.74%
- LYEL N/A
- EPS Growth
- PINE N/A
- LYEL N/A
- EPS
- PINE 0.14
- LYEL N/A
- Revenue
- PINE $52,227,000.00
- LYEL $61,000.00
- Revenue This Year
- PINE $8.21
- LYEL N/A
- Revenue Next Year
- PINE $4.37
- LYEL N/A
- P/E Ratio
- PINE $118.64
- LYEL N/A
- Revenue Growth
- PINE 14.42
- LYEL N/A
- 52 Week Low
- PINE $14.33
- LYEL $0.48
- 52 Week High
- PINE $19.42
- LYEL $3.15
- Technical
- Relative Strength Index (RSI)
- PINE 57.80
- LYEL 42.63
- Support Level
- PINE $16.22
- LYEL $0.53
- Resistance Level
- PINE $16.50
- LYEL $0.63
- Average True Range (ATR)
- PINE 0.26
- LYEL 0.07
- MACD
- PINE 0.06
- LYEL -0.01
- Stochastic Oscillator
- PINE 88.79
- LYEL 22.27
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.